|
Treatment related leukaemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Considering that the MLL-CBP fusion gene is also found almost exclusively in therapy-related leukemia, the association of MLL-p300 and MLL-CBP with therapy-related leukemia rather than de novo leukemia is thereby suggested.
|
18778367 |
2008 |
|
Treatment related leukaemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Leukemias with MLL translocations have been the topic of intense interest because of the unusual, biphenotypic immunophenotype of these leukemias, because of the unique clinical presentation of some MLL translocations (infant leukemia and therapy-related leukemia), and because of the large number of different chromosomal loci that partner with MLL in these translocations.
|
16797254 |
2006 |
|
Treatment related leukaemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We used a culture system of primary human hematopoietic CD34+ cells and inverse polymerase chain reaction to characterize the spectrum of stable genomic rearrangements promoted by etoposide exposure originating within an MLL translocation hotspot in therapy-related leukemia.
|
15528316 |
2005 |
|
Treatment related leukaemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, we cloned genomic breakpoints of the MLL and CBP genes in the t(11;16) in the SN-1 cell line and in five patients with therapy-related leukemia, all of whom had received topo II inhibitors for previous tumors.
|
15334549 |
2004 |
|
Treatment related leukaemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To discover genetic polymorphisms that may predispose patients to t-AML development, we sequenced the 8.3-kb MLL breakpoint cluster region (BCR) from 22 patients who had been treated with topo II inhibitors and who developed t-AML and from 37 patients who did not, and from eight infants and 20 normal individuals.
|
12665971 |
2003 |
|
Treatment related leukaemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our case is of interest because of simultaneous relapse of the original leukemia and onset of therapy-related leukemia and relatively rare t(1;11)(p32;q23) translocation with confirmed MLL/AF-1p fusion.
|
14704037 |
2003 |
|
Treatment related leukaemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Translocations involving the MLL gene at 11q23 are a frequent finding in therapy-related leukemia and are concentrated within a short, 8.3-kb tract of DNA, the breakpoint cluster region.
|
11389089 |
2001 |
|
Treatment related leukaemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Mixed Lineage Leukemia (MLL) gene is frequently rearranged in leukemia, especially in infantile leukemia and therapy-related leukemia.
|
11697487 |
2001 |
|
Treatment related leukaemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genomic organization, tissue expression, and cellular localization of AF3p21, a fusion partner of MLL in therapy-related leukemia.
|
11241789 |
2001 |
|
Treatment related leukaemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The MLL-AF9 fusion gene is associated with de novo acute myelo-genous leukemia (AML), rarely with acute lymphocytic leukemia (ALL) and with therapy related leukemia (t-AML).
|
10861294 |
2000 |
|
Treatment related leukaemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Following the development of therapy-related leukemia after 1 year, evolution of therapy-related AML-M4 with t(11;17)(q23;q25) and the rearrangement of the MLL gene were observed, while AML/MTG8 disappeared.
|
10905055 |
2000 |
|
Treatment related leukaemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further analysis of MSF may help to delineate the function of MLL partner genes in leukemia, particularly in therapy-related leukemia.
|
10339604 |
1999 |
|
Treatment related leukaemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Association of germline p53 mutation with MLL segmental jumping translocation in treatment-related leukemia.
|
9616138 |
1998 |
|
Treatment related leukaemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The translocation t(9;11)(p22;q23), which results in the fusion of MLL to AF9, is the most common of the 11q23 chromosomal abnormalities observed in de novo acute myeloid leukemia (AML), in therapy related leukemia (t-AML), and rarely in acute lymphoblastic leukemia (ALL).
|
9331569 |
1997 |